Mostrar el registro sencillo del ítem
Effects of estrogens and androgens on mitochondria under normal and pathological conditions
dc.contributor.author | Mohajeri M. | |
dc.contributor.author | Martín-Jiménez C. | |
dc.contributor.author | Barreto G.E. | |
dc.contributor.author | Sahebkar A. | |
dc.date.accessioned | 2020-09-02T22:23:04Z | |
dc.date.available | 2020-09-02T22:23:04Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1016/j.pneurobio.2019.03.001 | |
dc.identifier.citation | 176, , 54-72 | |
dc.identifier.issn | 03010082 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/5354 | |
dc.description | Several lines of evidence have suggested that mitochondrial dysfunction plays a key role in neurodegeneration. The mitochondrial function is a potential target for steroid hormones, which could exert protective activities in the brain and other tissues. The decrease of some sex steroids with aging has been associated with deleterious effects on brain function and progression to neurodegenerative diseases. Recent in vitro and in vivo evidence provides the basis for this review on the interplay of sex steroids and mitochondrial defects in preventing or improving pathological events in the central nervous system (CNS). In this article, the role of mitochondria under normal and pathological states will be discussed. In addition, we will review studies conducted on steroidal compounds, which have neuroprotective effects targeting mitochondria. It has been shown that these compounds could exert both direct and indirect effects on mitochondria that promote or preserve mitochondrial function under pathological circumstances, such as acute brain injury and chronic neurodegeneration. © 2019 Elsevier Ltd | |
dc.language.iso | en | |
dc.publisher | Elsevier Ltd | |
dc.subject | Acute | |
dc.subject | Androgens | |
dc.subject | Brain | |
dc.subject | diseases | |
dc.subject | Estrogens | |
dc.subject | injury | |
dc.subject | Mitochondria | |
dc.subject | Neurodegenerative | |
dc.subject | androgen | |
dc.subject | estradiol | |
dc.subject | estrogen | |
dc.subject | estrogen receptor alpha | |
dc.subject | estrogen receptor beta | |
dc.subject | raloxifene | |
dc.subject | tamoxifen | |
dc.subject | testosterone | |
dc.subject | tibolone | |
dc.subject | androgen | |
dc.subject | estrogen | |
dc.subject | neuroprotective agent | |
dc.subject | Alzheimer disease | |
dc.subject | amyotrophic lateral sclerosis | |
dc.subject | brain cell | |
dc.subject | brain injury | |
dc.subject | cell death | |
dc.subject | cerebrovascular accident | |
dc.subject | chronic disease | |
dc.subject | drug mechanism | |
dc.subject | energy yield | |
dc.subject | Friedreich ataxia | |
dc.subject | human | |
dc.subject | Huntington chorea | |
dc.subject | in vitro study | |
dc.subject | in vivo study | |
dc.subject | mitochondrion | |
dc.subject | nerve degeneration | |
dc.subject | neurologic disease | |
dc.subject | nonhuman | |
dc.subject | Parkinson disease | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | animal | |
dc.subject | degenerative disease | |
dc.subject | drug effect | |
dc.subject | female | |
dc.subject | male | |
dc.subject | metabolism | |
dc.subject | mitochondrion | |
dc.subject | Androgens | |
dc.subject | Animals | |
dc.subject | Brain Injuries | |
dc.subject | Estrogens | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Mitochondria | |
dc.subject | Nerve Degeneration | |
dc.subject | Neurodegenerative Diseases | |
dc.subject | Neuroprotective Agents | |
dc.title | Effects of estrogens and androgens on mitochondria under normal and pathological conditions | |
dc.type | Review |